Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Glycobiotechnology of the Insect Cell-Baculovirus Expression System Technology.

Palomares LA, Srivastava IK, Ramírez OT, Cox MMJ.

Adv Biochem Eng Biotechnol. 2018 Jun 10. doi: 10.1007/10_2018_61. [Epub ahead of print]

PMID:
29886511
2.

Improved stability of recombinant hemagglutinin using a formulation containing sodium thioglycolate.

Rhodes DG, Holtz K, Robinson P, Wang K, McPherson CE, Cox MM, Srivastava IK.

Vaccine. 2015 Nov 4;33(44):6011-6. doi: 10.1016/j.vaccine.2015.09.029. Epub 2015 Sep 26.

PMID:
26409814
3.

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.

Vassell R, He Y, Vennakalanti P, Dey AK, Zhuang M, Wang W, Sun Y, Biron-Sorek Z, Srivastava IK, LaBranche CC, Montefiori DC, Barnett SW, Weiss CD.

PLoS One. 2015 Jun 18;10(6):e0128562. doi: 10.1371/journal.pone.0128562. eCollection 2015.

4.

Dissolved carbon dioxide determines the productivity of a recombinant hemagglutinin component of an influenza vaccine produced by insect cells.

Meghrous J, Khramtsov N, Buckland BC, Cox MM, Palomares LA, Srivastava IK.

Biotechnol Bioeng. 2015 Nov;112(11):2267-75. doi: 10.1002/bit.25634. Epub 2015 Jul 14.

PMID:
25943562
5.

Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevent cross-linked multimer formation and potency loss.

Holtz KM, Robinson PS, Matthews EE, Hashimoto Y, McPherson CE, Khramtsov N, Reifler MJ, Meghrous J, Rhodes DG, Cox MM, Srivastava IK.

BMC Biotechnol. 2014 Dec 24;14:111. doi: 10.1186/s12896-014-0111-y.

6.

Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops.

Moscoso CG, Xing L, Hui J, Hu J, Kalkhoran MB, Yenigun OM, Sun Y, Paavolainen L, Martin L, Vahlne A, Zambonelli C, Barnett SW, Srivastava IK, Cheng RH.

Sci Rep. 2014 Nov 14;4:7025. doi: 10.1038/srep07025.

7.

Mechanism of a decrease in potency for the recombinant influenza A virus hemagglutinin H3 antigen during storage.

Hickey JM, Holtz KM, Manikwar P, Joshi SB, McPherson CE, Buckland B, Srivastava IK, Middaugh CR, Volkin DB.

J Pharm Sci. 2014 Mar;103(3):821-7. doi: 10.1002/jps.23848. Epub 2014 Jan 14.

PMID:
24425059
8.

Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein.

Kassa A, Dey AK, Sarkar P, Labranche C, Go EP, Clark DF, Sun Y, Nandi A, Hartog K, Desaire H, Montefiori D, Carfi A, Srivastava IK, Barnett SW.

PLoS One. 2013 Oct 16;8(10):e76139. doi: 10.1371/journal.pone.0076139. eCollection 2013.

9.

Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation of the effects of polyanions.

Kramer RM, Zeng Y, Sahni N, Kueltzo LA, Schwartz RM, Srivastava IK, Crane L, Joshi SB, Volkin DB, Middaugh CR.

J Pharm Sci. 2013 Dec;102(12):4305-14. doi: 10.1002/jps.23749. Epub 2013 Oct 15.

10.

Putative role of Tat-Env interaction in HIV infection.

Poon S, Moscoso CG, Xing L, Kan E, Sun Y, Kolatkar PR, Vahlne AG, Srivastava IK, Barnett SW, Cheng RH.

AIDS. 2013 Sep 24;27(15):2345-54. doi: 10.1097/01.aids.0000432453.60733.b2.

PMID:
23835500
11.

HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.

Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Cossut MR, Tripiciano A, Nappi F, Longo O, Bellino S, Picconi O, Fanales-Belasio E, Borsetti A, Toschi E, Schiavoni I, Bacigalupo I, Kan E, Sernicola L, Maggiorella MT, Montin K, Porcu M, Leone P, Leone P, Collacchi B, Palladino C, Ridolfi B, Falchi M, Macchia I, Ulmer JB, Buttò S, Sgadari C, Magnani M, Federico MP, Titti F, Banci L, Dallocchio F, Rappuoli R, Ensoli F, Barnett SW, Garaci E, Ensoli B.

PLoS One. 2012;7(11):e48781. doi: 10.1371/journal.pone.0048781. Epub 2012 Nov 13.

12.

Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants.

Lai RP, Seaman MS, Tonks P, Wegmann F, Seilly DJ, Frost SD, LaBranche CC, Montefiori DC, Dey AK, Srivastava IK, Sattentau Q, Barnett SW, Heeney JL.

PLoS One. 2012;7(4):e35083. doi: 10.1371/journal.pone.0035083. Epub 2012 Apr 11.

13.

Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.

Dey AK, Burke B, Sun Y, Hartog K, Heeney JL, Montefiori D, Srivastava IK, Barnett SW.

Vaccine. 2012 Apr 5;30(17):2749-59. doi: 10.1016/j.vaccine.2012.02.027. Epub 2012 Feb 22.

14.

Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein.

Dey AK, Burke B, Sun Y, Sirokman K, Nandi A, Hartog K, Lian Y, Geonnotti AR, Montefiori D, Franti M, Martin G, Carfi A, Kessler P, Martin L, Srivastava IK, Barnett SW.

PLoS One. 2012;7(1):e30233. doi: 10.1371/journal.pone.0030233. Epub 2012 Jan 24.

15.

Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic.

Martin G, Burke B, Thaï R, Dey AK, Combes O, Ramos OH, Heyd B, Geonnotti AR, Montefiori DC, Kan E, Lian Y, Sun Y, Abache T, Ulmer JB, Madaoui H, Guérois R, Barnett SW, Srivastava IK, Kessler P, Martin L.

J Biol Chem. 2011 Jun 17;286(24):21706-16. doi: 10.1074/jbc.M111.232272. Epub 2011 Apr 12. Erratum in: J Biol Chem. 2011 Aug 19;286(33):29442. Ramos, Oscar H P [added].

16.

A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.

Ferrantelli F, Maggiorella MT, Schiavoni I, Sernicola L, Olivieri E, Farcomeni S, Pavone-Cossut MR, Moretti S, Belli R, Collacchi B, Srivastava IK, Titti F, Cafaro A, Barnett SW, Ensoli B.

Vaccine. 2011 Apr 5;29(16):2918-32. doi: 10.1016/j.vaccine.2011.02.006. Epub 2011 Feb 21.

PMID:
21338681
17.

Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.

Dey AK, Srivastava IK.

Expert Rev Vaccines. 2011 Feb;10(2):227-51. doi: 10.1586/erv.10.142. Review.

PMID:
21105782
18.

Structural evidence of glycoprotein assembly in cellular membrane compartments prior to Alphavirus budding.

Soonsawad P, Xing L, Milla E, Espinoza JM, Kawano M, Marko M, Hsieh C, Furukawa H, Kawasaki M, Weerachatyanukul W, Srivastava R, Barnett SW, Srivastava IK, Cheng RH.

J Virol. 2010 Nov;84(21):11145-51. doi: 10.1128/JVI.00036-10. Epub 2010 Aug 25.

19.

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.

Barnett SW, Burke B, Sun Y, Kan E, Legg H, Lian Y, Bost K, Zhou F, Goodsell A, Zur Megede J, Polo J, Donnelly J, Ulmer J, Otten GR, Miller CJ, Vajdy M, Srivastava IK.

J Virol. 2010 Jun;84(12):5975-85. doi: 10.1128/JVI.02533-09. Epub 2010 Apr 14.

20.

Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.

Burke B, Gómez-Román VR, Lian Y, Sun Y, Kan E, Ulmer J, Srivastava IK, Barnett SW.

Virology. 2009 Apr 25;387(1):147-56. doi: 10.1016/j.virol.2009.02.005. Epub 2009 Feb 27.

21.

A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide.

Martin G, Sun Y, Heyd B, Combes O, Ulmer JB, Descours A, Barnett SW, Srivastava IK, Martin L.

Virology. 2008 Nov 25;381(2):241-50. doi: 10.1016/j.virol.2008.08.039. Epub 2008 Oct 2.

22.

Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin.

Caputo A, Brocca-Cofano E, Castaldello A, Voltan R, Gavioli R, Srivastava IK, Barnett SW, Cafaro A, Ensoli B.

Vaccine. 2008 Feb 26;26(9):1214-27. doi: 10.1016/j.vaccine.2007.12.030. Epub 2008 Jan 15.

PMID:
18243435
23.

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.

Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, Cristillo AD, Ferrai MG, Weiss DE, Letvin NL, Montefiori D, Pal R, Vajdy M.

AIDS. 2008 Jan 30;22(3):339-48. doi: 10.1097/QAD.0b013e3282f3ca57.

PMID:
18195560
24.

Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates.

Srivastava IK, Kan E, Sun Y, Sharma VA, Cisto J, Burke B, Lian Y, Hilt S, Biron Z, Hartog K, Stamatatos L, Diaz-Avalos R, Cheng RH, Ulmer JB, Barnett SW.

Virology. 2008 Mar 15;372(2):273-90. Epub 2007 Dec 3. Erratum in: Virology. 2008 Nov 25;381(2):287. Diaz-Avalos, Ruben [added].

25.

Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.

Bråve A, Hinkula J, Cafaro A, Eriksson LE, Srivastava IK, Magnani M, Ensoli B, Barnett SW, Wahren B, Rollman E.

Vaccine. 2007 Sep 28;25(39-40):6882-90. Epub 2007 Jul 27.

PMID:
17707956
26.

Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.

Derby NR, Gray S, Wayner E, Campogan D, Vlahogiannis G, Kraft Z, Barnett SW, Srivastava IK, Stamatatos L.

Virology. 2007 Sep 30;366(2):433-45. Epub 2007 Jun 8.

27.

Direct inactivation of human immunodeficiency virus type 1 by a novel small-molecule entry inhibitor, DCM205.

Duong YT, Meadows DC, Srivastava IK, Gervay-Hague J, North TW.

Antimicrob Agents Chemother. 2007 May;51(5):1780-6. Epub 2007 Feb 16.

28.

Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein.

Xu R, Srivastava IK, Greer CE, Zarkikh I, Kraft Z, Kuller L, Polo JM, Barnett SW, Stamatatos L.

AIDS Res Hum Retroviruses. 2006 Oct;22(10):1022-30.

PMID:
17067273
29.

Role of neutralizing antibodies in protective immunity against HIV.

Srivastava IK, Ulmer JB, Barnett SW.

Hum Vaccin. 2005 Mar-Apr;1(2):45-60. Epub 2005 Mar 17. Review.

PMID:
17038830
30.

Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.

Burke B, Derby NR, Kraft Z, Saunders CJ, Dai C, Llewellyn N, Zharkikh I, Vojtech L, Zhu T, Srivastava IK, Barnett SW, Stamatatos L.

Virology. 2006 Nov 25;355(2):138-51. Epub 2006 Aug 22.

31.
32.

Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.

Sharma VA, Kan E, Sun Y, Lian Y, Cisto J, Frasca V, Hilt S, Stamatatos L, Donnelly JJ, Ulmer JB, Barnett SW, Srivastava IK.

Virology. 2006 Aug 15;352(1):131-44. doi: 10.1016/j.virol.2006.04.030.

33.

Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.

Xu R, Srivastava IK, Kuller L, Zarkikh I, Kraft Z, Fagrouch Z, Letvin NL, Heeney JL, Barnett SW, Stamatatos L.

Virology. 2006 Jun 5;349(2):276-89. Epub 2006 Mar 9.

34.

Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.

Barnett SW, Srivastava IK, Ulmer JB, Donnelly JJ, Rappuoli R.

Microbes Infect. 2005 Nov;7(14):1386-91. Epub 2005 Sep 20.

PMID:
16275150
35.

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

Srivastava IK, Ulmer JB, Barnett SW.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S33-52. Review.

PMID:
15285704
36.

Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen.

Leung L, Srivastava IK, Kan E, Legg H, Sun Y, Greer C, Montefiori DC, zur Megede J, Barnett SW.

AIDS. 2004 Apr 30;18(7):991-1001.

PMID:
15096801
37.

Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Srivastava IK, Stamatatos L, Kan E, Vajdy M, Lian Y, Hilt S, Martin L, Vita C, Zhu P, Roux KH, Vojtech L, C Montefiori D, Donnelly J, Ulmer JB, Barnett SW.

J Virol. 2003 Oct;77(20):11244-59.

38.

Gene vaccines.

Srivastava IK, Liu MA.

Ann Intern Med. 2003 Apr 1;138(7):550-9. Review.

PMID:
12667025
39.
40.

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

Srivastava IK, Stamatatos L, Legg H, Kan E, Fong A, Coates SR, Leung L, Wininger M, Donnelly JJ, Ulmer JB, Barnett SW.

J Virol. 2002 Mar;76(6):2835-47.

41.

Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites.

Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB.

Mol Microbiol. 1999 Aug;33(4):704-11.

42.

A mechanism for the synergistic antimalarial action of atovaquone and proguanil.

Srivastava IK, Vaidya AB.

Antimicrob Agents Chemother. 1999 Jun;43(6):1334-9.

43.
45.

Identification and purification of glucose phosphate isomerase of Plasmodium falciparum.

Srivastava IK, Schmidt M, Grall M, Certa U, Garcia AM, Perrin LH.

Mol Biochem Parasitol. 1992 Sep;54(2):153-64.

PMID:
1435856
46.

Plasmodium falciparum: identification and purification of the phosphoglycerate kinase of the malaria parasite.

Grall M, Srivastava IK, Schmidt M, Garcia AM, Mauël J, Perrin LH.

Exp Parasitol. 1992 Aug;75(1):10-8.

PMID:
1639156
47.

Comparative evaluation of an ELISA based on recombinant polypeptides and IFA for serology of malaria.

Srivastava IK, Schmidt M, Grall M, Yerly S, Garcia AM, Bouvier M, Takacs B, Dobeli H, Perrin LH.

J Trop Med Hyg. 1991 Jun;94(3):189-94.

PMID:
2051524
48.

Expression, purification, biochemical characterization and inhibition of recombinant Plasmodium falciparum aldolase.

Döbeli H, Trzeciak A, Gillessen D, Matile H, Srivastava IK, Perrin LH, Jakob PE, Certa U.

Mol Biochem Parasitol. 1990 Jun;41(2):259-68.

PMID:
2204832
49.

Specificity and inhibitory activity of antibodies to Plasmodium falciparum aldolase.

Srivastava IK, Schmidt M, Certa U, Döbeli H, Perrin LH.

J Immunol. 1990 Feb 15;144(4):1497-503.

PMID:
2406342
50.

Recombinant polypeptides for serology of malaria.

Srivastava IK, Takacs B, Caspers P, Certa U, McGregor IA, Scaife J, Perrin LH.

Trans R Soc Trop Med Hyg. 1989 May-Jun;83(3):317-21.

PMID:
2694465

Supplemental Content

Loading ...
Support Center